Company: AZN
Filing Date: 2025-09-22
Form Type: 6-K
Source: 0001654954-25-010967
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-09-22
Form: 6-K
Chunk 6
---
 the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html . [Last accessed: September 2025].

12. Jong-Gyun J, et al. Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis. Int J Mol Sci . 2023;24(18):14229. doi: 10.3390/ijms241814229.

13. Varricchi G , et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol. 2018;9:1595.

14. Xolair (omalizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf . [Last accessed: September 2025].

15. Xolair (omalizumab) US prescribing information. Available at: https://www.gene.com/download/pdf/xolair_prescribing.pdf . [Last accessed: September 2025].

16. Nucala (mepolizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf . [Last accessed: September 2025].

17. Nucala (mepolizumab) US prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761122s006,125526s018lbl.pdf . [Last accessed: September 2025].

18. Dupixent (dupilumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf . [Last accessed: September 2025].

19. Dupixent (dupilumab) US prescribing information. Available at: https://www.regeneron.com/downloads/dupixent_fpi.pdf . [Last accessed: September 2025].

20. Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https://clinicaltrials.gov/ct2/show/NCT048